Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Aspirin-Exacerbated Respiratory Disease (MARINER)
NCT05575037Phase 2Active, not recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Aug 2023
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dupilumab in Aspirin Exacerbated Respiratory Disease (AERD), chronic rhinosinusitis with nasal polyposis (CRSwNP), sponsored by Brigham and Women's Hospital. Started Aug 2023; status: active, not recruiting.
02
Drugs
03
Conditions
Aspirin Exacerbated Respiratory Disease (AERD)chronic rhinosinusitis with nasal polyposis (CRSwNP)
Beyond the preview
Go deeper on NCT05575037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05575037.